Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum

Opiorphin and sialorphin are two recently discovered endogenous enkephalin‐degrading enzyme inhibitors. Our aim was to characterize their effect on the mouse ileum motility and to investigate the role of glutamine in position 1. Opiorphin, sialorphin, and their analogs substituted in position 1 with pyroglutamic acid (pGlu) were synthesized by the solid‐phase method using Fmoc chemistry. The effect of peptides on gastrointestinal (GI) motility was characterized using in vitro assays and in mouse model of upper GI transit. Opiorphin and sialorphin, but not their analogs, significantly increased electrical field‐stimulated contractions in the mouse ileum in a δ‐opioid receptor‐dependent manner. Opiorphin, sialorphin, and their analogs did not influence the effect of [Met5]enkephalin on smooth muscle contractility in the mouse ileum in vitro. [Met5]enkephalin and sialorphin, but not opiorphin injected intravenously (1 mg/kg), significantly inhibited the upper GI transit. The intraperitoneal administration of peptides (3 mg/kg) did not change the mouse upper GI transit. In conclusion, this is the first study investigating the effect of opiorphin and sialorphin on the mouse ileum motility and demonstrating that glutamine in position 1 is crucial for their pharmacological action. Our results may be important for further structure–activity relationship studies on opiorphin and sialorphin and future development of potent clinical therapeutics aiming at the enkephalinergic system. Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd. In the present study, we characterized the effect of opiorphin and sialorphin on the mouse ileum motility in vitro and in vivo. We also examined whether glutamine residue in position 1 is crucial for the pharmacological action of these peptides.